Goldman Sachs (GS) reported on Friday that they have lowered their rating for Cree, Inc. (CREE). The firm has downgraded CREE from ‘Neutral’ to ‘Sell’.

Cree Inc. recently traded at $24.64, a loss of $2.38 over Thursday’s closing price. The name has a current market capitalization of $2.54 billion.

Analysts at Monness Crespi & Hardt downgraded Iconix Brand Group, Inc. (ICON) from ‘Buy’ to ‘Neutral’ in a research report issued to clients on Friday.

On valuation measures, Iconix Brand Group Inc. stock it’s trading at a forward P/E multiple of 3.26x, and at a multiple of 2.80x this year’s estimated earnings. The t-12-month revenue at Iconix Brand Group Inc. is $391.08 million. ICON ‘s ROE for the same period is 14.45%.

Valeant Pharmaceuticals International, Inc. (VRX) was reiterated a ‘Buy’ at Guggenheim. The firm however, slashed its price target on the name by 35% to $195 from $300.

Shares of VRX have gained $3.45 to $82.22 in midday trading on Friday, giving it a market cap of roughly $28 billion. The stock traded as high as $263.81 on August 6, 2015.

Analysts at Jefferies downgraded Repligen Corporation (RGEN) from ‘Buy’ to ‘Hold’ in a research report issued to clients on Friday.

Shares of the $866.53 million market cap company are up 31.63% year-over-year and 63.54% year-to-date. Repligen Corp., currently with a median Wall Street price target of $38 and a high target of $44, dropped $6.05 to $26.33 in recent trading.

The Men’s Wearhouse, Inc. (MW) was downgraded by Goldman from a ‘Buy’ rating to a ‘Neutral’ rating in a research report issued to clients today.

MW closed at $40.10 on Thursday and is currently trading down $17.33. In the past 52 weeks, shares of Houston, Texas-based specialty apparel retailer have traded between a low of $21.44 and a high of $66.18 and are now trading at $22.77.